Exelixis (NASDAQ: EXEL), the South San Francisco-based developer of cancer drugs, saw its shares climb 32 percent to $6.23 today after reporting on clinical trial results for its lead product candidate against prostate cancer. The company reported that 19 out of 20 patients who got its experimental XL184 treatment had at least partial clearance of lesions on their bones where the cancer had spread. The findings were released at the EORTC-NCI-AACR meeting in Berlin, Germany. Xconomy reported on what this clinical trial data means to Exelixis in an in-depth feature story last month.
By posting a comment, you agree to our terms and conditions.